Open AccessReset osmostat: Facts and controversies
Author(s) -
J. M. Feder,
José María Cubero Gómez,
F Serra-Aguirre,
Carlos Guido Musso
Publication year - 2019
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_307_17
Subject(s) - hyponatremia , medicine , hypernatremia , plasma osmolality , intensive care medicine , reset (finance) , pediatrics , sodium , vasopressin , chemistry , organic chemistry , economics , financial economics
Reset osmostat (RO) consists of a change in the normal plasma osmolality threshold (reduction or increase), which consequently induces chronic dysnatremia (hyponatremia or hypernatremia). Although the early papers on RO state that hyponatremic patients with this condition are usually not symptomatic, the current view is that most patients with hyponatremia are symptomatic and should be treated. RO has been associated with a myriad of clinical conditions and has clear diagnostic criteria which are crucial to arrive at the correct diagnosis and treatment.